Elan (ELN) was up yet again this month as all signs continue to point to an FDA approval of the reintroduction of their multiple sclerosis drug Tysabri at the end of June. CEO Kelly Martin, indicated Elan and partner, Biogen Idec (BIIB), may raise the price of Tysabri treatment depending on final labeling related to potential risks….
